American Journal of Kidney Diseases
Volume 52, Issue 1 , Pages 93-101 , July 2008

Reduction in β2-Microglobulin With Super-flux Versus High-flux Dialysis Membranes: Results of a 6-Week, Randomized, Double-blind, Crossover Trial

  • Rebecca Pellicano, MBBS, FRACP

      Affiliations

    • Department of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia
    • Department of Medicine, Monash University, Clayton, Victoria, Australia.
    • Corresponding Author InformationAddress correspondence to Rebecca Pellicano, MBBS, FRACP, Department of Nephrology, Monash Medical Centre, 246 Clayton Rd, Clayton, Victoria, Australia, 3168.
    • ,
  • Kevan R. Polkinghorne, BHB, MClinEpi, MBChB, FRACP, PhD

      Affiliations

    • Department of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia
    • Department of Medicine, Monash University, Clayton, Victoria, Australia.
    • ,
  • Peter G. Kerr, MBBS, PhD, FRACP

      Affiliations

    • Department of Nephrology, Monash Medical Centre, Clayton, Victoria, Australia
    • Department of Medicine, Monash University, Clayton, Victoria, Australia.

Received 23 August 2007 ,Accepted 12 February 2008.

References 

  1. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol. 1999;10:1606–1615
  2. Kalantar-Zadeh K. Causes and consequences of the reverse epidemiology of body mass index in dialysis patients. J Ren Nutr. 2005;15:142–147
  3. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248
  4. Zager PG, Nikolic J, Brown RH, et al. “U” Curve association of blood pressure and mortality in hemodialysis patients (Medical Directors of Dialysis Clinic, Inc). Kidney Int. 1998;54:561–569
  5. Boure T, Vanholder R. Biochemical and clinical evidence for uremic toxicity. Artif Organs. 2004;28:248–253
  6. Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int. 2003;63:1934–1943
  7. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med. 2002;347:2010–2019
  8. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity: Report from the National Cooperative Dialysis Study. N Engl J Med. 1981;305:1176–1181
  9. Cheung AK, Rocco MV, Yan G, et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: Results of the HEMO Study. J Am Soc Nephrol. 2006;17:546–555
  10. Locatelli F. Membrane Permeability Outcome: Results From the MPO Study. In: XLIV ERA-EDTA Congress, Barcelona, Spain, June 21-24. 2007;
  11. Krieter DH, Lemke HD, Canaud B, Wanner C. Beta(2)-microglobulin removal by extracorporeal renal replacement therapies. Biochim Biophys Acta. 2005;1753:146–153
  12. Lin CL, Huang CC, Yu CC, Yang HY, Chuang FR, Yang CW. Reduction of advanced glycation end product levels by on-line hemodiafiltration in long-term hemodialysis patients. Am J Kidney Dis. 2003;42:524–531
  13. Locatelli F, Di Filippo S, Manzoni C. Removal of small and middle molecules by convective techniques. Nephrol Dial Transplant. 2000;15(suppl 2):S37–S44
  14. Morena MD, Guo D, Balakrishnan VS, Brady JA, Winchester JF, Jaber BL. Effect of a novel adsorbent on cytokine responsiveness to uremic plasma. Kidney Int. 2003;63:1150–1154
  15. Floridi A, Antolini F, Galli F, Fagugli RM, Floridi E, Buoncristiani U. Daily haemodialysis improves indices of protein glycation. Nephrol Dial Transplant. 2002;17:871–878
  16. Friedman AN, Bostom AG, Levey AS, Rosenberg IH, Selhub J, Pierratos A. Plasma total homocysteine levels among patients undergoing nocturnal versus standard hemodialysis. J Am Soc Nephrol. 2002;13:265–268
  17. Maduell F, Navarro V, Torregrosa E, et al. Change from three times a week on-line hemodiafiltration to short daily on-line hemodiafiltration. Kidney Int. 2003;64:305–313
  18. Ward RA. Protein-leaking membranes for hemodialysis: A new class of membranes in search of an application?. J Am Soc Nephrol. 2005;16:2421–2430
  19. Locatelli F, Andrulli S, Pecchini F, et al. Effect of high-flux dialysis on the anaemia of haemodialysis patients. Nephrol Dial Transplant. 2000;15:1399–1409
  20. Niwa T, Asada H, Tsutsui S, Miyazaki T. Efficient removal of albumin-bound furancarboxylic acid by protein-leaking hemodialysis. Am J Nephrol. 1995;15:463–467
  21. Bonomini M, Fiederling B, Bucciarelli T, Manfrini V, Di Ilio C, Albertazzi A. A new polymethylmethacrylate membrane for hemodialysis. Int J Artif Organs. 1996;19:232–239
  22. Stein G, Franke S, Mahiout A, et al. Influence of dialysis modalities on serum AGE levels in end-stage renal disease patients. Nephrol Dial Transplant. 2001;16:999–1008
  23. De Vriese AS, Langlois M, Bernard D, et al. Effect of dialyser membrane pore size on plasma homocysteine levels in haemodialysis patients. Nephrol Dial Transplant. 2003;18:2596–2600
  24. Galli F, Benedetti S, Buoncristiani U, et al. The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels. Kidney Int. 2003;64:748–755
  25. Van Tellingen A, Grooteman MP, Bartels PC, et al. Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients. Kidney Int. 2001;59:342–347
  26. De Smet R, Dhondt A, Eloot S, Galli F, Waterloos MA, Vanholder R. Effect of the super-flux cellulose triacetate dialyser membrane on the removal of non-protein-bound and protein-bound uraemic solutes. Nephrol Dial Transplant. 2007;22:2006–2012
  27. Tessitore N, Lapolla A, Arico NC, et al. Effect of protein leaking BK-F PMMA-based hemodialysis on plasma pentosidine levels. J Nephrol. 2004;17:707–714
  28. Galli F, Benedetti S, Floridi A, et al. Glycoxidation and inflammatory markers in patients on treatment with PMMA-based protein-leaking dialyzers. Kidney Int. 2005;67:750–759
  29. van Tellingen A, Grooteman MP, Schoorl M, et al. Enhanced long-term reduction of plasma leptin concentrations by super-flux polysulfone dialysers. Nephrol Dial Transplant. 2004;19:1198–1203
  30. Bergstrom J, Wehle B. No change in corrected beta 2-microglobulin concentration after cuprophane haemodialysis. Lancet. 1987;1:628–629
  31. Argiles A, Ficheux A, Thomas M, et al. Precise quantification of dialysis using continuous sampling of spent dialysate and total dialysate volume measurement. Kidney Int. 1997;52:530–537
  32. Ronco C, Bowry SK, Brendolan A, et al. Hemodialyzer: From macro-design to membrane nanostructure; The case of the FX-class of hemodialyzers. Kidney Int Suppl. 2002;80:126–142
  33. Kerr PG, Sutherland WH, de Jong S, Vaithalingham I, Williams SM, Walker RJ. The impact of standard high-flux polysulfone versus novel high-flux polysulfone dialysis membranes on inflammatory markers: A randomized, single-blinded, controlled clinical trial. Am J Kidney Dis. 2007;49:533–539
  34. Kerr PB, Argiles A, Flavier JL, Canaud B, Mion CM. Comparison of hemodialysis and hemodiafiltration: A long-term longitudinal study. Kidney Int. 1992;41:1035–1040
  35. Ward RA, Schmidt B, Hullin J, Hillebrand GF, Samtleben W. A comparison of on-line hemodiafiltration and high-flux hemodialysis: A prospective clinical study. J Am Soc Nephrol. 2000;11:2344–2350
  36. Canaud B, Assounga A, Kerr P, Aznar R, Mion C. Failure of a daily haemofiltration programme using a highly permeable membrane to return beta 2-microglobulin concentrations to normal in haemodialysis patients. Nephrol Dial Transplant. 1992;7:924–930
  37. Ward RA, Greene T, Hartmann B, Samtleben W. Resistance to intercompartmental mass transfer limits beta2-microglobulin removal by post-dilution hemodiafiltration. Kidney Int. 2006;69:1431–1437
  38. Raj DS, Ouwendyk M, Francoeur R, Pierratos A. Beta(2)-microglobulin kinetics in nocturnal haemodialysis. Nephrol Dial Transplant. 2000;15:58–64
  39. Kalantar-Zadeh K, Ikizler TA, Block G, Avram MM, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients: Causes and consequences. Am J Kidney Dis. 2003;42:864–881
  40. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999;55:648–658
  41. Stenvinkel P, Heimburger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999;55:1899–1911
  42. Schindler R, Christ-Kohlrausch F, Frei U, Shaldon S. Differences in the permeability of high-flux dialyzer membranes for bacterial pyrogens. Clin Nephrol. 2003;59:447–454
  43. Wanner C, Bahner U, Mattern R, Lang D, Passlick-Deetjen J. Effect of dialysis flux and membrane material on dyslipidaemia and inflammation in haemodialysis patients. Nephrol Dial Transplant. 2004;19:2570–2575
  44. Combe C, McCullough KP, Asano Y, Ginsberg N, Maroni BJ, Pifer TB. Kidney Disease Outcomes Quality Initiative (K/DOQI) and the Dialysis Outcomes and Practice Patterns Study (DOPPS): Nutrition guidelines, indicators, and practices. Am J Kidney Dis. 2004;44:39–46
  45. Lowrie EG, Lew NL. Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990;15:458–482
  46. Owen WF, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N Engl J Med. 1993;329:1001–1006
  47. Caravaca F, Arrobas M, Dominguez C. Serum albumin and other serum protein fractions in stable patients on peritoneal dialysis. Perit Dial Int. 2000;20:703–707
  48. Cooper S, Iliescu EA, Morton AR. The relationship between dialysate protein loss and membrane transport status in peritoneal dialysis patients. Adv Perit Dial. 2001;17:244–247
  49. Prinsen BH, Rabelink TJ, Beutler JJ, et al. Increased albumin and fibrinogen synthesis rate in patients with chronic renal failure. Kidney Int. 2003;64:1495–1504
  50. Comper WD, Osicka TM. Albumin-like material in urine. Kidney Int Suppl. 2004;92:S65–S66
  51. Strong KJ, Osicka TM, Comper WD. Urinary-peptide excretion by patients with and volunteers without diabetes. J Lab Clin Med. 2005;145:239–246
  52. Ward RA, Brinkley KA. A proteomic analysis of proteins removed by ultrafiltration during extracorporeal renal replacement therapy. Contrib Nephrol. 2004;141:280–291
  53. Danielski M, Ikizler TA, McMonagle E, et al. Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis. 2003;42:286–294
  54. Himmelfarb J. Relevance of oxidative pathways in the pathophysiology of chronic kidney disease. Cardiol Clin. 2005;23:319–330

 Originally published online as doi:10.1053/j.ajkd.2008.02.296 on April 15, 2008.

 Trial Registration: www.anzctr.org.au; study number: 12606000132549.

PII: S0272-6386(08)00466-6

doi: 10.1053/j.ajkd.2008.02.296

American Journal of Kidney Diseases
Volume 52, Issue 1 , Pages 93-101 , July 2008

Article Tools

* Image Usage & Resolution